NasdaqGM:SCYX

Stock Analysis Report

Executive Summary

SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States.

Snowflake

Fundamentals

Excellent balance sheet with high growth potential.

Risks

  • SCYNEXIS has significant price volatility in the past 3 months.

Share Price & News

How has SCYNEXIS's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

3.6%

NasdaqGM:SCYX

-0.6%

US Pharmaceuticals

0.3%

US Market


1 Year Return

-36.6%

NasdaqGM:SCYX

6.1%

US Pharmaceuticals

0.7%

US Market

SCYX underperformed the Pharmaceuticals industry which returned 6% over the past year.

SCYX underperformed the Market in United States of America which returned 0.8% over the past year.


Share holder returns

SCYXIndustryMarket
7 Day3.6%-0.6%0.3%
30 Day-19.4%0.2%0.4%
90 Day-32.9%-3.0%0.6%
1 Year-36.6%-36.6%8.6%6.1%2.9%0.7%
3 Year-56.2%-56.2%17.2%9.0%47.0%37.2%
5 Year-86.4%-86.4%27.5%13.8%54.7%37.4%

Price Volatility Vs. Market

How volatile is SCYNEXIS's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is SCYNEXIS undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

SCYNEXIS's share price is below the future cash flow value, and at a moderate discount (> 20%).

SCYNEXIS's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

SCYNEXIS is loss making, we can't compare its value to the US Pharmaceuticals industry average.

SCYNEXIS is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for SCYNEXIS, we can't assess if its growth is good value.


Price Based on Value of Assets

SCYNEXIS is overvalued based on assets compared to the US Pharmaceuticals industry average.


Next Steps

Future Growth

How is SCYNEXIS expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

43.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

SCYNEXIS's revenue is expected to grow significantly at over 20% yearly.

SCYNEXIS's earnings are expected to grow significantly at over 20% yearly.

SCYNEXIS's revenue growth is expected to exceed the United States of America market average.

SCYNEXIS's earnings growth is expected to exceed the United States of America market average.

SCYNEXIS's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if SCYNEXIS will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has SCYNEXIS performed over the past 5 years?

6.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

SCYNEXIS does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare SCYNEXIS's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare SCYNEXIS's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if SCYNEXIS has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if SCYNEXIS has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if SCYNEXIS improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is SCYNEXIS's financial position?


Financial Position Analysis

SCYNEXIS is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

SCYNEXIS's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

SCYNEXIS's level of debt (161.5%) compared to net worth is high (greater than 40%).

SCYNEXIS had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 2.2x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

SCYNEXIS has sufficient cash runway for 1.4 years based on current free cash flow.

SCYNEXIS has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of -3.2% each year.


Next Steps

Dividend

What is SCYNEXIS's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate SCYNEXIS's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate SCYNEXIS's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as SCYNEXIS has not reported any payouts.

Unable to verify if SCYNEXIS's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as SCYNEXIS has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of SCYNEXIS's salary, the management and board of directors tenure and is there insider trading?

3.8yrs

Average management tenure


CEO

Marco Taglietti (58yo)

4.2yrs

Tenure

US$1,114,895

Compensation

Dr. Marco Taglietti, M.D. has been the Chief Executive Officer of SCYNEXIS, Inc. since April 1, 2015 and has been President since September 24, 2015. Dr. Taglietti served as Senior Vice President, Head of  ...


CEO Compensation Analysis

Marco's remuneration is higher than average for companies of similar size in United States of America.

Marco's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

3.8yrs

Average Tenure

48yo

Average Age

The tenure for the SCYNEXIS management team is about average.


Board Age and Tenure

4.0yrs

Average Tenure

59yo

Average Age

The tenure for the SCYNEXIS board of directors is about average.


Insider Trading

More shares have been bought than sold by SCYNEXIS insiders in the past 3 months, but not in substantial volumes.


Recent Insider Transactions

BuyUS$40,75018 Apr 19
Marco Taglietti
EntityIndividual
Role
CEO, President & Director
Member of the Board of Directors
Shares25,000
Max PriceUS$1.63
BuyUS$17,25014 Jan 19
Marco Taglietti
EntityIndividual
Role
CEO, President & Director
Member of the Board of Directors
Shares25,000
Max PriceUS$0.69
BuyUS$11,50002 Jan 19
Marco Taglietti
EntityIndividual
Role
CEO, President & Director
Member of the Board of Directors
Shares25,000
Max PriceUS$0.46
BuyUS$5,95102 Jan 19
David Angulo
EntityIndividual
Role
Chief Medical Officer
Shares12,000
Max PriceUS$0.50
BuyUS$8,89010 Sep 18
David Angulo
EntityIndividual
Role
Chief Medical Officer
Shares7,000
Max PriceUS$1.27
BuyUS$32,25027 Aug 18
Marco Taglietti
EntityIndividual
Role
CEO, President & Director
Member of the Board of Directors
Shares25,000
Max PriceUS$1.29

Ownership Breakdown


Management Team

  • Marco Taglietti (58yo)

    CEO, President & Director

    • Tenure: 4.2yrs
    • Compensation: $1.11m
  • David Angulo (53yo)

    Chief Medical Officer

    • Tenure: 4.0yrs
    • Compensation: $768.61k
  • Eric Francois (43yo)

    Chief Financial Officer

    • Tenure: 3.6yrs
    • Compensation: $664.70k
  • Scott Sukenick (40yo)

    General Counsel & Corporate Secretary

    • Tenure: 1.6yrs

Board Members

  • Armando Anido (60yo)

    Director

    • Tenure: 0.4yrs
  • Dave Hastings (57yo)

    Independent Director

    • Tenure: 3.8yrs
    • Compensation: $72.75k
  • Ann Hanham (65yo)

    Independent Director

    • Tenure: 10.5yrs
    • Compensation: $72.75k
  • Guy MacDonald (59yo)

    Chairman of the Board

    • Tenure: 4.0yrs
    • Compensation: $81.83k
  • Steve Gilman (65yo)

    Independent Director

    • Tenure: 4.3yrs
    • Compensation: $69.00k
  • Pat Machado (54yo)

    Independent Director

    • Tenure: 3.8yrs
    • Compensation: $72.50k
  • Marco Taglietti (58yo)

    CEO, President & Director

    • Tenure: 4.6yrs
    • Compensation: $1.11m

Company Information

SCYNEXIS, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: SCYNEXIS, Inc.
  • Ticker: SCYX
  • Exchange: NasdaqGM
  • Founded: 1999
  • Industry: pharmaceuticals
  • Sector: pharmaceuticals & biotech
  • Market Cap: US$62.235m
  • Shares outstanding: 53.65m
  • Website: Click here

Number of Employees


Location

  • SCYNEXIS, Inc.
  • 1 Evertrust Plaza
  • 13th Floor
  • Jersey City
  • New Jersey
  • 7302
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SCYXNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJan 1970
135DB (Deutsche Boerse AG)YesCommon StockDEEURJan 1970

Biography

SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intrave ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/06/17 00:48
End of Day Share Price2019/06/14 00:00
Earnings2019/03/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.